How to evaluate emerging technologies in cervical cancer screening?
Open Access
- 22 July 2009
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 125 (11), 2489-2496
- https://doi.org/10.1002/ijc.24774
Abstract
Excellent recommendations exist for studying therapeutic and diagnostic questions. We observe that good guidelines on assessment of evidence for screening questions are currently lacking. Guidelines for diagnostic research (STARD), involving systematic application of the reference test (gold standard) to all subjects of large study populations, are not pertinent in situations of screening for disease that is currently not yet present. A five‐step framework is proposed for assessing the potential use of a biomarker as a screening tool for cervical cancer: i ) correlation studies establishing a trend between the rate of biomarker expression and severity of neoplasia; ii ) diagnostic studies in a clinical setting where all women are submitted to verification by the reference standard; iii ) biobank‐based studies with assessment in archived cytology samples of the biomarker in cervical cancer cases and controls; iv ) prospective cohort studies with baseline assessment of the biomarker and monitoring of disease; v ) randomised intervention trials aiming to observe reduced incidence of cancer (or its surrogate, severe dysplasia) in the experimental arm at subsequent screening rounds. The 5‐phases framework should guide researchers and test developers in planning assessment of new biomarkers and protect clinicians and stakeholders against premature claims for insufficiently evaluated products. © 2009 UICC.Keywords
This publication has 79 references indexed in Scilit:
- p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysisCancer Treatment Reviews, 2009
- HPV Screening for Cervical Cancer in Rural IndiaThe New England Journal of Medicine, 2009
- Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-scienceGynecologic Oncology, 2009
- Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trialThe Lancet Oncology, 2008
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008
- Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and IndiaInternational Journal of Cancer, 2008
- Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trialThe Lancet, 2007
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerThe New England Journal of Medicine, 2007
- Chapter 9: Clinical applications of HPV testing: A summary of meta-analysesVaccine, 2006
- Clinical utility of HPV–DNA detection: Triage of minor cervical lesions, follow-up of women treated for high-grade CIN: An update of pooled evidenceGynecologic Oncology, 2005